Anti-HLA-DR/anti-DOTA diabody construction in a modular gene design platform: Bispecific antibodies for pretargeted radioimmunotherapy

Cancer Biotherapy and Radiopharmaceuticals

Volumn 16, Issue 6, 2001, Pages 525-535

  DeNardo, D G ^a   Xiong, C Y ^a   Shi, X B ^a   DeNardo, G L ^a   DeNardo, S J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bispecific antibodies; Diabodies; Immunoglobulin fragments; Pretargeting; Radioimmunotherapy; Recombinant antibodies

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; BISPECIFIC ANTIBODY; DIABODY; HLA DR ANTIGEN; IMMUNOGLOBULIN FRAGMENT; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; MONOCLONAL ANTIBODY; RECOMBINANT ANTIBODY; RECOMBINANT IMMUNOGLOBULIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BACTERIOPHAGE; CYTOPLASM; DNA LIBRARY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE CONSTRUCT; ISOTOPE LABELING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RADIOIMMUNOTHERAPY;

EID: 0035660721     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/10849780152752128     Document Type: Article

References (59)

1. Treatment of a patient with B cell lymphoma by 1-131 Lym-1 monoclonal antibodies
2. Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using 1-131 Lym-1 monoclonal antibody
3. 131-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma
4. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas
5. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma
6. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma
7. 90Y-labeled humanized LL2 anti-CD22 monoclonal antibody (MAb) in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL)
8. Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10
9. 67Copper-2-imino-thiolane-6-[p-(bromoacetamido) benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma
10. Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL)
11. A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugates
12. Yttrium-90/Indium-111-DOTA-peptide-Chimeric L6: Pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer
13. 90Y-DOTA-biotin
14. 90Y-DOTA-biotin with pretargeted NR-LU-10/SA
15. Labeling monoclonal antibodies with 90yttrium- and 111indium-DOTA chelates: A simple and efficient method
16. Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3)
17. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors
18. Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions
19. Man-made antibodies
20. Tumor localization of anti-CEA single-chain Fvs: Improved targeting by non-covalent dimers
21. Highly specific in vivo tumour targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv
22. Making antibody fragments using phage display libraries
23. Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli
24. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library
25. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms
26. Construction, binding properties, metabolism, and targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49
27. Making antibodies by phage display technology
28. Development of a hyperimmune anti-MUC-1 single chain antibody phage display library for targeting breast cancer
29. Phage library-derived human anti-TETA and anti-DOTA ScFv for pretargeting RIT
30. Production of human antibody repertoires in transgenic mice
31. Human antibodies with subnanomolar affinities isolated from a large non-immunized phage display library
32. Toward the production of bispecific antibody fragments for clinical applications
33. Designing and optimizing library selection strategies for generating high-affinity antibodies
34. Tumor pretargeting: Almost the bottom line
35. Editorial: Pretargeted peptide imaging and therapy
36. Phage libraries for generation of clinically useful antibodies
37. Multi-subunit proteins on the surface of filamentous phage: Methodologies for displaying antibody (Fab) heavy and light chains
38. Phage antibodies: Filamentous phage displaying antibody variable domains
39. Human antibody engineering
40. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human-B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential
41. New anti-Cu-TETA and anti-Y-DOTA monoclonal antibodies for potential use in the pretargeted delivery of radiopharmaceuticals to tumor
42. High level secretion of a humanized bispecific diabody from Escherichia coli
43. Current protocols in molecular biology
44. Anti-Tac (Fv)-PE40, a single chain antibody Pseudomonas fusion protein directed at interleukin 2 receptor bearing cells
45. A comparison of strategies to stabilize immunoglobulin Fv-fragments
46. Screening of phage antibody libraries
47. Immunochemical aspects of monoclonal antibodies important for radiopharmaceutical development
48. Stable bifunctional chelates of metals used in radiotherapy
49. Production of single-stranded plasmid DNA
50. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications
51. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site
52. Isolation of highaffinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection
53. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies
54. A new era for radiolabeled antibodies in cancer?
55. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: Enhanced divalent hapten affinity for cell-bound antibody conjugate
56. Targeting of indium-111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: Imaging of tumors hosted in nude mice
57. Radioimmunodetection of medullary thyroid carcinoma using Indium-111 bivalent hapten and anti-CEA X anti-DTPA-Indium bispecific antibody
58. Pretargeting with the affinity enhancement system for radioimmunotherapy